COMMUNIQUÉS West-GlobeNewswire

Galapagos Announces Appointment of Fred Blakeslee as General Counsel
16/10/2025
Mechelen, Belgium ; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, [...]
RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting
16/10/2025
ALISO VIEJO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
16/10/2025
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide [...]
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
16/10/2025
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell [...]
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
16/10/2025
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the [...]
Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026
16/10/2025
Marking 14 years of continuous operation, millions of transactions, and demonstrated reliability across the global blockchain ecosystem, Litecoin sets the benchmark for longevity and performance as digital assets evolve [...]
WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective October 21, 2025
16/10/2025
Hangzhou, China, Oct. 16, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
LifeStance to Host Third Quarter 2025 Earnings Conference Call on November 6, 2025
16/10/2025
SCOTTSDALE, Ariz., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter 2025 earnings [...]
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
16/10/2025
Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression FDA designation follows previously [...]
atai Life Sciences Announces Proposed Public Offering of Common Shares
16/10/2025
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health [...]
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
16/10/2025
AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after [...]
Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details
16/10/2025
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on [...]
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
16/10/2025
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today [...]
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
16/10/2025
Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPP The CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN, Mass., Oct. 16, 2025 ( [...]
AVITA Medical Announces CEO Transition
17/10/2025
Board Chairman Cary Vance appointed Interim CEO Board member Jan Stern Reed appointed Lead Independent Director Third quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, [...]
Celebrating 50 Years of Katena: From One Woman’s Vision to a Global Legacy in Ophthalmology
16/10/2025
Honoring five decades of precision, partnership, and innovation that continue to shape the future of eye care PARSIPPANY, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a global medical technology company, is [...]
Wounded Warriors Family Support Donates 2025 Ford F-150 Truck to Retired Marines Veteran
16/10/2025
KING OF PRUSSIA, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- A deserving veteran received the life-changing gift of mobility after a considerable donation Tuesday at Topgolf King of Prussia . Wounded Warriors Family Support [...]
AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute
16/10/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE PRESENTE LES PREMIÈRES DONNÉES DE PHASE 1 DE LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN RECHUTE Paris, le 16 octobre 2025 [...]
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
16/10/2025
PRESS RELEASE AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 16 October 2025, 9pm CET AB Science SA ( [...]

Pages